Current Research

Markus Müschen explores oncogenic signaling in B cell-derived leukemia and lymphomas. Unlike other types of cancer, B cell tumors are subject to an autoimmunity checkpoint. As with normal B cells, B cell tumor cells are weeded out if they are self-reactive. Müschen uses pharmacological agents to engage autoimmunity checkpoints in B cell tumors, with the ultimate goal of overcoming resistance to conventional drug-treatment.

Find a Scientist